Milnacipran

Generic Name: Milnacipran

Brand Names: Savella

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂N_₂O

CAS Number: 92623-85-3

Unique Ingredient Identifier: G56VK1HF36

Background: Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression . Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional ...

Indication: Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the management of fibromyalgia in patients that are 18 years old or above .
...

Associated Conditions: Fibromyalgia

Associated Therapies: -

Clinical Trials

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia

Phase 4

Completed

Conditions: Sleep
Sleep Disorders
Fibromyalgia

Interventions: Drug: Placebo
Drug: Milnacipran

First Posted Date: 2010-11-04

Last Posted Date: 2019-08-21

Lead Sponsor: Mansoor Ahmed M.D.

Target Recruit Count: 19

Registration Number: NCT01234675

Locations: 🇺🇸
Cleveland Sleep Research Center, Middleburg Heights, Ohio, United States

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Milnacipran

First Posted Date: 2010-10-21

Last Posted Date: 2018-03-29

Lead Sponsor: University of California, Los Angeles

Target Recruit Count: 18

Registration Number: NCT01225991

Locations: 🇺🇸
UCLA Semel Institute, Los Angeles, California, United States

Effect of Milnacipran in Chronic Neuropathic Low Back Pain

Phase 2

Completed

Conditions: Low Back Pain

Interventions: Drug: Placebo
Drug: Milnacipran

First Posted Date: 2010-10-20

Last Posted Date: 2014-01-17

Lead Sponsor: Northwestern University

Target Recruit Count: 40

Registration Number: NCT01225068

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran

Phase 3

Withdrawn

Conditions: Back Pain

Interventions: Drug: Savella

First Posted Date: 2010-10-15

Last Posted Date: 2017-01-12

Lead Sponsor: Brigham and Women's Hospital

Registration Number: NCT01221740

Locations: 🇺🇸
Brigham and Women's Hospital Pain Trials Center, Chestnut Hill, Massachusetts, United States

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

Phase 4

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Milnacipran
Drug: Placebo

First Posted Date: 2010-09-23

Last Posted Date: 2014-11-17

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 49

Registration Number: NCT01207453

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia

Phase 4

Completed

Conditions: Fibromyalgia

Interventions: Drug: Placebo
Drug: milnacipran

First Posted Date: 2010-07-30

Last Posted Date: 2017-11-08

Lead Sponsor: University of Michigan

Target Recruit Count: 22

Registration Number: NCT01173055

Locations: 🇺🇸
University of Michigan, Chronic Pain and Fatigue Research Center, Ann Arbor, Michigan, United States

Study of Fibromyalgia Treated With Milnacipran

Phase 4

Completed

Conditions: Fibromyalgia

Interventions: Drug: Milnacipran
Procedure: Skin Biopsy

First Posted Date: 2010-05-18

Last Posted Date: 2020-01-09

Lead Sponsor: Albany Medical College

Target Recruit Count: 27

Registration Number: NCT01125423

Locations: 🇺🇸
Upstate Clinical Research, LLC, Albany, New York, United States

The Effect of Milnacipran in Patients With Fibromyalgia

Phase 2

Completed

Conditions: Fibromyalgia

Interventions: Drug: Placebo
Drug: Milnacipran

First Posted Date: 2010-04-22

Last Posted Date: 2016-06-30

Lead Sponsor: Beth Israel Medical Center

Target Recruit Count: 37

Registration Number: NCT01108731

Locations: 🇺🇸
Pain and Fatigue Study Center - Beth Israel Medical Center, New York, New York, United States

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

Phase 4

Completed

Conditions: Fibromyalgia

Interventions: Drug: Placebo
Drug: Milnacipran

First Posted Date: 2010-03-01

Last Posted Date: 2012-01-26

Lead Sponsor: Forest Laboratories

Target Recruit Count: 107

Registration Number: NCT01077375

Locations: 🇺🇸
Forest Investigative Site 003, Cleveland, Ohio, United States
🇺🇸
Forest Investigative Site 024, Atlanta, Georgia, United States
🇺🇸
Forest Investigative Site 010, Jackson, Mississippi, United States

and more 23 locations

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

Phase 4

Completed

Conditions: Fibromyalgia

Interventions: Drug: Placebo
Drug: Milnacipran

First Posted Date: 2009-11-17

Last Posted Date: 2011-09-07

Lead Sponsor: Forest Laboratories

Target Recruit Count: 340

Registration Number: NCT01014585

Locations: 🇺🇸
Forest Investigative Site 060, Pembroke Pines, Florida, United States
🇺🇸
Forest Investigative Site 009, Atlanta, Georgia, United States
🇺🇸
Forest Investigative Site 008, Worcester, Massachusetts, United States

and more 55 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy